Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1768-1770

  Ibrahim, Ashraf S ^a,b   Gebremariam, Teclegiorgis ^a   Luo, Guanpingsheng ^a   Fu, Yue ^a,b   French, Samuel W ^a,b   Edwards Jr , John E ^a,b   Spellberg, Brad ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; DEFERASIROX; MICAFUNGIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IRON CHELATION; LUNG ASPERGILLOSIS; MONOTHERAPY; MOUSE; MUCORMYCOSIS; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL; RHIZOPUS ORYZAE; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; IRON CHELATING AGENTS; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; MUCORMYCOSIS; POLYENES; RHIZOPUS;

EID: 79953197208     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01577-10     Document Type: Article

References (25)

1. Bowman, J. C., et al. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
2. Caston-Osorio, J. J., A. Rivero, and J. Torre-Cisneros. 2008. Epidemiology of invasive fungal infection. Int. J. Antimicrob. Agents 32(Suppl. 2):S103-S109.
3. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
4. Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
5. Hissen, A. H., A. N. Wan, M. L. Warwas, L. J. Pinto, and M. M. Moore. 2005. The Aspergillus fumigatus siderophore biosynthetic gene sidA, encoding L-ornithine N5-oxygenase, is required for virulence. Infect. Immun. 73:5493-5503.
6. Ibrahim, A. S., V. Avanessian, B. Spellberg, and J. E. Edwards, Jr. 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47:3343-3344.
7. Ibrahim, A. S., et al. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.
8. Ibrahim, A. S., et al. 2007. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 117:2649-2657.
9. Ibrahim, A. S., T. Gebremariam, S. W. French, J. E. Edwards, Jr., and B. Spellberg. 2010. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 65:289-292.
10. Ibrahim, A. S., T. Gebremariam, Y. Fu, J. E. Edwards, Jr., and B. Spellberg. 2008. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob. Agents Chemother. 52:1556-1558.
11. Ibrahim, A. S., et al. 2010. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol. Microbiol. 77:587-604.
12. Ibrahim, A. S., B. Spellberg, and J. Edwards, Jr. 2008. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr. Opin. Infect. Dis. 21:620-625.
13. Kerl, K., et al. 24 August 2010, posting date. Catheter-associated aspergillosis of the chest wall following allogeneic hematopoietic stem cell transplantation. Transpl. Infect. Dis. doi:10.1111/j.1399-3062.2010.00559.x.
14. Kontoyiannis, D. P., and G. P. Bodey. 2002. Invasive aspergillosis in 2002: an update. Eur. J. Clin. Microbiol. Infect. Dis. 21:161-172.
15. Kontoyiannis, D. P., et al. 2007. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110:1303-1306. (Pubitemid 47435602)
16. Mihu, C. N., et al. 2010. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer 116:5290-5296.
17. Olson, J. A., et al. 2010. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob. Agents Chemother. 54:3884-3894.
18. Reed, C., et al. 2008. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 47:364-371.
19. Sheppard, D. C., et al. 2004. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 48:1908-1911.
20. Spellberg, B., et al. 2009. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob. Agents Chemother. 53:3122-3125.
21. Spellberg, B., J. Edwards Jr., and A. Ibrahim. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569.
22. Spellberg, B., Y. Fu, J. E. Edwards, Jr., and A. S. Ibrahim. 2005. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49:830-832.
23. Spreghini, E., et al. 2009. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53:4035-4039.
24. Takazono, T., et al. 2009. Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 53:3508-3510.
25. Wilson, D. T., R. H. Drew, and J. R. Perfect. 2009. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 168:313-327.